Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (281)	10/11/2005 1:36:19 AM
From: tuck	Read Replies (2) \| Respond to of 447

>>Then why is he still whining about Goddard being Goddard?)<< I get in trouble with Rick if I attempt to portray his thinking, so I'll let him do it if he's going to. Anyhow, here's the S-4/A: sec.gov Eyetech special meeting November 10th. We can always hope EYET shareholders are greedy and vote against the merger. Low odds, for sure. Even more unlikely, we can hope for a better competing bid. Then OSI would get 31 million as a termination fee. Definitely the best case scenario; odds: 1 in 100. After Hours action in OSIP today was interesting. It lost some more ground at first, then came back to nearly the closing price late in the session, apparently when DNA explained the Tarceva shortfall. What scrip data I've seen looks choppy but trending slightly up. That seems right to you? Wholesaler inventories are apparently even choppier, but if DNA's explanation is correct, we should see better sales. So I'm guessing we have a near term bottom. The deal will in all likelyhood close, and I think that's been priced in, as has earnings (slight possible upside if European wholesalers were not overstocked?). OSIP should be pretty safe until the ANCHOR data comes out. Pardon me if I'm being obvious here. Cheers, Tuck